会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Inhibition of HIV infection through chemoprophylaxis
    • 通过化学预防来抑制艾滋病毒感染
    • US09044509B2
    • 2015-06-02
    • US11669547
    • 2007-01-31
    • Walid M. HeneineThomas M. FolksRobert JanssenRonald OttenJose Gerardo Garcia Lerma
    • Walid M. HeneineThomas M. FolksRobert JanssenRonald OttenJose Gerardo Garcia Lerma
    • A61K31/675A61K31/505A61K45/06A61K31/7072A61K31/513
    • A61K31/675A61K9/0034A61K9/0053A61K31/513A61K31/683A61K31/7072A61K45/06A61K2300/00
    • A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.
    • 提供了一种保护灵长类动物宿主免受免疫缺陷逆转录病毒的自身复制感染的过程。 在暴露于免疫缺陷型逆转录病毒之前,通过向灵长类动物宿主施用药学有效量的核苷逆转录酶抑制剂和药学有效量的核苷酸逆转录酶抑制剂的组合来实现保护。 如果在暴露后24小时内以单一剂量提供,则该药物是有效的。 定期日剂量的方案对于在感染灵长类动物宿主后免疫缺陷逆转录病毒变得自我复制也是有效的。 用于控制群体内的逆转录病毒传播的方法包括在性暴露于免疫缺陷型逆转录病毒来源之前对具有高免疫缺陷型逆转录病毒感染的细菌组合的高风险亚群的施用,以排除免疫缺陷型逆转录病毒在自身复制中的自我复制 一个亚群的成员。
    • 5. 发明授权
    • Method and kit for detecting resistance to antiviral drugs
    • 检测抗病毒药物耐药性的方法和试剂盒
    • US07691572B2
    • 2010-04-06
    • US11054023
    • 2005-02-09
    • Walid M. HeneineGerardo Garcia-LermaShinji YamamotoWilliam M. SwitzerThomas M. Folks
    • Walid M. HeneineGerardo Garcia-LermaShinji YamamotoWilliam M. SwitzerThomas M. Folks
    • C12Q1/70A61K39/21
    • C12Q1/702
    • Assays and kits for the detection of phenotypic resistance of a retrovirus to reverse transcriptase inhibitor-drugs in a biological sample. The assays are based on the direct analysis of the susceptibility of retroviral reverse transcriptase to inhibition by a reverse transcriptase inhibitor drug. The enzymatic activity of the reverse transcriptase is determined by measuring the DNA product produced when an RNA template and a first complementary DNA primer from a suitable region of the encephalomyocarditis virus genome are incubated with a biological sample containing reverse transcriptase in the presence of the drug to which resistance is being determined. The DNA product is amplified and detection of the amplified DNA indicates resistance to the drug employed in the assay. Detection of relatively greater amounts of amplified DNA when certain drugs are used indicates the presence of multiple nucleoside analog resistant strains or mutations.
    • 用于检测逆转录病毒逆转录酶抑制剂药物在生物样品中的表型抗性的测定和试剂盒。 该测定法基于逆转录病毒逆转录酶对逆转录酶抑制剂药物的抑制的易感性的直接分析。 通过测量在来自脑心肌炎病毒基因组的合适区域的RNA模板和第一个互补DNA引物与含有逆转录酶的生物样品在药物存在下孵育时产生的DNA产物来测定逆转录酶的酶活性, 正在确定哪个阻力。 DNA产物被扩增,扩增的DNA的检测表明对测定中使用的药物具有抗性。 当使用某些药物时检测相对较大量的扩增DNA表明存在多种核苷类似物抗性菌株或突变。